Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Samsung Bioepis Co., Ltd.

News headline image
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Releases Second Quarter 2026 US Biosimilar Market Report
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Releases First Quarter 2026 US Biosimilar Market Report, Providing Updates to Evolving Drug Pricing Models
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis’ Second Quarter 2025 Biosimilar Market Report Highlights US Debut of Ustekinumab Biosimilars with WAC discounts over 80% and Regulatory Streamlining
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
From Samsung Bioepis Co., Ltd.
Via Business Wire
News headline image
FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva
From Samsung Bioepis Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.